News
Filter
Sort by Date

Press Release

Walden Biosciences to Present Phase 1+ and Phase 2 Data for WAL0921 at American Society of Nephrology Kidney Week

October 2, 2026

Press Release

Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease

September 15, 2026

Press Release

Walden Biosciences to Participate in 24th Annual Morgan Stanley Global Healthcare Conference

September 8, 2026

Press Release

Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases

September 4, 2025

Press Release

Walden Biosciences Appoints Howard Mayer, M.D. to Board of Directors

January 28, 2025

Press Release

Walden Biosciences Highlights 2024 Accomplishments and 2025 Priorities

January 10, 2025